VALBIOTIS : Investors presentation – March 2021

VALBIOTIS

INVESTORS PRESENTATION

March 2021

01.

02.

03.

04.

05.

06.

2

VALBIOTIS / Corporate

TOTUM-63, to reduce the risk of type 2 diabetes

TOTUM-070, to reduce hypercholesterolemia

TOTUM-854, to reduce blood pressure

TOTUM-448, to reduce non-alcoholic hepatic steatosis (NAFL)

FINANCIAL INFORMATION

© NON CONFIDENTIAL

A R&D company, committed	3
to scientific innovation,
for preventing and combating
metabolic diseases

Active substances from plants and based on science, to address unmet medical needs

• An innovative approach,
  enabled by a specific expertise of plants
• A high level of evidence, with clinical studies and health claims
• A pipeline of innovative active substances in Nutrition Healthcare, engineered in our R&D centers
• 4 patent families registered on 5 continents

© NON CONFIDENTIAL

4

Nutrition Healthcare:

a portfolio of active substances, in clinical stages

	Phase II	Phase II/III	Study launch	Results
TOTUM-63 / Prediabetes
		Mid-2020	S1 2022

TOTUM-070 / Hypercholesterolemia
	Q4 2020	S1 2022

TOTUM-854 / Arterial hypertension
	S1 2021	2022

TOTUM-448 / Fatty Liver
	S2 2021	-

The success of an innovative model in health industry, proven effective in only 6 years

2020

2019

2017

5

First strategic partnership with a global healthcare player

• Up to 71 M CHF upfront and milestones payments
• • Royalties on net sales
  • Supply revenue

Development of other products of the pipeline following TOTUM-63 standard

Initial Public Offering

• Internalization of the R&D platform
• Strategic patents granted for TOTUM-63
• Clinical validation of the first product, TOTUM-63
• 36 employees
• 1200m2 R&D platform in-house

Foundation of VALBIOTIS

2016

2014

• First fundraising
• Discovery of TOTUM-63: first studies and patent applications
• 4 employees and academic partners

© NON CONFIDENTIAL

27.2 million euros

raised since 2014 (equity)